Table 2.

Pairwise model parameter comparison of PND2 whole body and PND21 liver, brain, and serum between treatment groups.

Groups compared	n	PLS components	R2Y (%)	Q2 (cumulative)
PND2
Whole body
Control/0.025 µg BPA	38	2	99.3	0.979
Control/0.25 µg BPA	34	2	99.4	0.970
Control/25 µg BPA	31	1	99.5	0.989
0.025 µg BPA/0.25 µg BPA	31	3	98.0	0.731
0.025 µg BPA/25 µg BPA	29	1	98.3	0.943
0.25 µg BPA/25 µg BPA	25	2	98.9	0.969
PND21
Liver
Control/0.025 µg BPA	21	1	89.7	0.822
Control/0.25 µg BPA	24	1	99.5	0.980
Control/25 µg BPA	24	2	99.7	0.990
0.025 µg BPA/0.25 µg BPA	23	3	99.5	0.896
0.025 µg BPA/25 µg BPA	24	3	99.4	0.950
0.25 µg BPA/25 µg BPA	26	2	98.8	0.928
Brain
Control/0.025 µg BPA	22	2	99.0	0.955
Control/0.25 µg BPA	22	2	99.0	0.963
Control/25 µg BPA	21	1	90.0	0.664
0.025 µg BPA/0.25 µg BPA	23	3	98.5	0.932
0.025 µg BPA/25 µg BPA	25	3	99.5	0.941
0.25 µg BPA/25 µg BPA	26	4	99.4	0.895
Serum
Control/0.025 µg BPA	23	3	99.6	0.826
Control/0.25 µg BPA	25	4	98.9	0.932
Control/25 µg BPA	23	3	99.8	0.991
0.025 µg BPA/0.25 µg BPA	26	3	96.3	0.891
0.025 µg BPA/25 µg BPA	23	2	99.0	0.937
0.25 µg BPA/25 µg BPA	26	3	99.3	0.973